Dr. Broder is Chief Medical Officer at Celera Genomics, former NCI Director
FREMONT, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Protein Design Labs,
Inc. (PDL) (Nasdaq: PDLI) today announced that Samuel Broder, M.D., has been
elected to the company's Board of Directors. Dr. Broder is a physician-
scientist with special expertise in the relationship between disorders of the
immune system and cancer. He currently is Chief Medical Officer at Celera
Genomics and Celera Diagnostics.
"We are delighted to welcome Sam to the PDL Board and are certain his
expertise in pharmaceutical research and development will be a major asset to
the company during this phase of growth," said Mark McDade, Chief Executive
Officer, PDL. "We have six products entering later-stage clinical trials. Dr.
Broder's background in clinical development will be invaluable as we aim to
commercialize these therapies for a range of serious medical conditions."
Dr. Broder has been Chief Medical Officer of Celera Genomics since joining
that company in 1998. He has broad responsibilities for medical affairs,
including the integration of genomic, biological and medical information.
Dr. Broder began his research career in the Metabolism Branch of the
National Cancer Institute (NCI) in 1972. Following the onset of the AIDS
epidemic, Dr. Broder's laboratory added studies of anti-retroviral agents to
its research repertoire and made significant contributions to the development
of AIDS drugs such as AZT ddl and ddC.
In 1989, President Ronald Reagan named Dr. Broder Director of the NCI.
Under his leadership, the NCI initiated a number of important large-scale
human trials in the prevention, diagnosis, and treatment of cancer. In the
spring of 1995, Dr. Broder became Senior Vice President for Research and
Development at the IVAX Corporation (now in process of being acquired by TEVA
Pharmaceutical Industries, Ltd.) in Florida, where he directed a broad range
of pharmaceutical research on new drugs for heart disease, diabetes and
diseases of the lung.
Dr. Broder received his bachelor's and medical degrees from the University
of Michigan. He is a member of the Institute of Medicine of the U.S. National
Academy of Sciences, is the author of more than 300 scholarly papers and holds
numerous patents.
About Protein Design Labs
PDL is a biopharmaceutical company focused on the research, development
and commercialization of novel therapies for inflammation and autoimmune
diseases, acute cardiac conditions and cancer. PDL markets several
biopharmaceutical products in the United States through its hospital sales
force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the
development of humanized antibodies, PDL has licensed its patents to numerous
pharmaceutical and biotechnology companies, some of which are now paying
royalties on net sales of licensed products. Further information on PDL is
available at http://www.pdl.com.
Protein Design Labs and the PDL logo are registered U.S. trademarks of
Protein Design Labs, Inc.
SOURCE Protein Design Labs, Inc.
 back to top
Related links:
http://www.pdl.com
CONTACT:
James R. Goff, Senior Director, Investor
Relations, of Protein Design Labs, Inc., +1-510-574-1421 or
jgoff@pdl.com
|
